<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839578</url>
  </required_header>
  <id_info>
    <org_study_id>2012.724</org_study_id>
    <nct_id>NCT01839578</nct_id>
  </id_info>
  <brief_title>Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances</brief_title>
  <acronym>RCA-SHA</acronym>
  <official_title>Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is responsible for 50% of all acute kidney injury (AKI) in intensive care units
      (ICUs), contributing greatly to multiple organ dysfunction syndrome (MODS). Special types of
      continuous renal replacement therapies (CRRT) have been proposed as adjuvant therapies for
      septic shock due to their ability to remove middle molecular weight molecules such as
      inflammatory mediators involved in MODS pathophysiology. These therapies are called
      extracorporeal &quot; blood purification &quot; therapies.

      When CRRT is used, an anticoagulation is required to prevent clotting of the extracorporeal
      circuit, possibly causing bleeding in selected patients. Many anticoagulation strategies have
      been proposed and the most commonly used in 2013 is still unfractionated heparin. Regional
      citrate anticoagulation (RCA) is an interesting alternative as it dramatically decreases the
      bleeding risk.

      The investigators hypothesize that the use of citrate with Super High Flux Continuous
      Veno-Venus Hemodialysis (SHF-CVVHD) would be highly beneficial over time by preserving the
      filter effectiveness via limiting protein adhesion (which subsequently reduces filter pore
      sizes (protein cake)), as compared to heparin. Consequently, higher clearances of the
      inflammatory mediators could be maintained over time with citrate as compared to heparin
      anticoagulation. In other words, for the same duration of filter use, middle molecular weight
      molecules and cytokines clearances would be greater with citrate as compared to heparin. To
      test this hypothesis, the investigators will perform a clinical randomized controlled trial
      which aim would be to compare middle molecular weight molecules and cytokines clearances in
      SHF-CVVHD using RCA versus systemic heparin anticoagulation in septic patients with AKI.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Middle molecular weight molecules clearances</measure>
    <time_frame>18 months</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), blood and post-filter samplings will be taken in order to calculate kappa and lambda light chains of immunoglobulin clearances.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearances of cytokines and molecules of interest</measure>
    <time_frame>T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), sampling will be simultaneously collected from blood and post-filter in order to determine cytokines (IL-1 ra, IL-10, IL-6, IL-8, β2microglobuline), urea, creatinine and albumin clearances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameters</measure>
    <time_frame>T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), clinical data and blood sampling will be collected in order to assess mean arterial pressure, heart rate, vasopressor requirement and lactate level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory parameters</measure>
    <time_frame>(T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h),</time_frame>
    <description>At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), PaO2/FIO2 ratio will be measured by blood sampling and clinical data collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28th day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>RCA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHF-CVVHD with regional citrate anticoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHF-CVVHD with systemic heparin anticoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)</intervention_name>
    <description>Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.
Ci-Ca protocole for MultiFiltrate® CRRT machine :
4% trisodium citrate solution
Calcium chloride solution (100 mmol/L)
Dialysate flow rate: 35 ml/kg/h
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3
Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.
Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.
Blood flow adapted to the acid-base status</description>
    <arm_group_label>RCA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)</intervention_name>
    <description>Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.
Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.
Standard dialysate for CRRT : Prismasol® K2 solution
Dialysate flow rate: 35 ml/kg/h
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of</description>
    <arm_group_label>Heparin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female critically ill patients over the age of 18 years old

          -  Acute Kidney Injury requiring CRRT defined using the Risk, Injury, Failure, Loss,
             End-stage renal disease (RIFLE) classification with criterion I or worse.

          -  Septic shock as defined by the American College of Chest Physicians/Society of
             Critical Care Medicine Consensus Conference.

          -  Written informed consent obtained from the patient or a patient's legal representative

          -  Patient patient's legal representative able to agree to patient's enrollment in the
             study with informed consent.

        Exclusion Criteria:

          -  Pregnancy

          -  Participation in another research study protocol

          -  Known heparin induced thrombopenia or contraindication to heparin

          -  Pre-existing chronic renal failure on chronic dialysis

          -  Therapeutic anticoagulation with heparin for another reason (e.g. chonic arrhythmia)

          -  Severe liver failure (15% prothrombin time)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Rimmelé, Dr</last_name>
    <phone>4 72 11 02 13</phone>
    <phone_ext>+33</phone_ext>
    <email>th.rimmele@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pr Bernard Allaouchiche, Pr</last_name>
    <phone>4 72 11 02 13</phone>
    <phone_ext>+33</phone_ext>
    <email>bernard.allaouchiche@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Réanimation - Pavillon P, Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Rimmelé, Dr</last_name>
      <phone>4 72 11 02 13</phone>
      <phone_ext>+33</phone_ext>
      <email>th.rimmele@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bernard Allaouchiche, Pr</last_name>
      <phone>4 72 11 02 13</phone>
      <phone_ext>+33</phone_ext>
      <email>bernard.allaouchiche@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Rimmelé, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Allaouchiche, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles-Eric Ber, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jullien Crozon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu Page, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanne Prothet, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Jacques Baillon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise Christin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Floccard, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Guillaume, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Martin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Marcotte, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Hautin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Faure, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Geffriaud, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Malavieille, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytokines</keyword>
  <keyword>blood purification</keyword>
  <keyword>super high flux hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

